...
首页> 外文期刊>Journal of Radiation Research >Results of definitive radiotherapy with concurrent chemotherapy for maxillary sinus carcinomas with neck lymph node metastasis
【24h】

Results of definitive radiotherapy with concurrent chemotherapy for maxillary sinus carcinomas with neck lymph node metastasis

机译:具有颈淋巴结转移的上颌窦癌并发化疗的明确放射治疗结果

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The purpose of this study was to describe the results of definitive radiotherapy (RT) with concurrent chemotherapy formaxillary sinus carcinomas (MSCs) with neck lymph node metastasis to clarify its limitation. Local control (LC), progression-free survival (PFS) and overall survival (OS) rates were calculated using the Kaplan-Meier method and were compared between subgroups using the log rank test. Toxicity was classified using common terminology criteria of adverse events version 5.0. Eighteen patients with inoperable MSC with neck lymph node metastasis including 12 men and 6 women with a median age of 67 years were analyzed. The histologic diagnoses were as follows: 16 patients had squamous cell carcinomas and 2 had other histology. Four patients had stage T3MSC, 6 had T4a and 8 had T4b. Among 18 patients, 7 received concurrent systemic chemotherapy and 11 received selective arterial chemoinfusion. The median follow-up period was 17 months. The 2-year LC, PFS and OS rates for the entire cohort were 34, 31 and 46%, respectively. No significant differences were observed for LC, PFS and OS rates between systemic chemotherapy and selective arterial chemo-infusion cohorts. Grade 3 or higher acute toxicity, including both non-hematological and hematological, was observed in nine patients (50%), while no grade 3 or higher late toxicity was observed. In conclusion, we described the results of definitive RT for MSCs with neck lymph node metastasis. Local recurrence of primary tumor was a frequent pattern of failure and it should be addressed in future study.
机译:本研究的目的是用颈淋巴结转移描述具有同时化疗形成鼻窦癌(MSC)的明确放疗(RT)的结果,以阐明其限制。使用Kaplan-Meier方法计算局部控制(LC),无进展生存期(PFS)和整体生存率(OS)率,并使用日志等级测试在子组之间进行比较。使用常见的术语5.0的常见术语标准进行分类毒性。分析了颈部淋巴结转移的十八患者,包括12名男子和6名患有67岁的男性和6名患者。组织学诊断如下:16名患者鳞状细胞癌,2例有其他组织学。四名患者有阶段T3MSC,6例具有T4A和8具有T4B。在18名患者中,7名接受并发全身化疗和11个接受的选择性动脉化疗。中位后续期间为17个月。整个队列的2年LC,PFS和OS税率分别为34,31和46%。对于全身化疗与选择性动脉化疗纳入群体之间的LC,PFS和OS速率没有观察到显着差异。在九名患者(50%)中观察到3级或更高的急性毒性,包括非血液学和血液学,而未观察到3级或更高的晚期毒性。总之,我们描述了具有颈淋巴结转移的MSC的最终RT的结果。原发性肿瘤的局部复发是经常失败的模式,应该在将来的研究中解决。

著录项

  • 来源
    《Journal of Radiation Research》 |2020年第1期|104-109|共6页
  • 作者单位

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Int Med Ctr Dept Head & Neck Surg Hidaka Japan;

    Saitama Med Univ Int Med Ctr Dept Head & Neck Surg Hidaka Japan;

    Saitama Med Univ Int Med Ctr Dept Head & Neck Surg Hidaka Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

    Saitama Med Univ Dept Radiat Oncol Int Med Ctr 1397-1 Yamane Hidaka Saitama 3501298 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    maxillary sinus carcinoma; neck lymph node metastasis; radiotherapy; concurrent chemotherapy; selective arterial chemo-infusion;

    机译:上颌窦癌;颈淋巴结转移;放射疗法;同时化疗;选择性动脉化疗输液;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号